[O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes

Drug Metabolism and Disposition

Volumn 25, Issue 9, 1997, Pages 1097-1100

  Rodrigues, A David ^a   Surber, Bruce W ^b   Yao, Y E ^b   Wong, Shekman L ^b   Roberts, Ellen M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ETHOXYRESORUFIN DEETHYLASE; PHENACETIN; UNSPECIFIC MONOOXYGENASE; CARBON; CYTOCHROME P450 1A2;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL LINE; MICHAELIS CONSTANT; PRIORITY JOURNAL; COMPARATIVE STUDY; ENZYMOLOGY; LIVER MICROSOME; METABOLISM;

CARBON RADIOISOTOPES; CYTOCHROME P-450 CYP1A2; HUMANS; MICROSOMES, LIVER; PHENACETIN;

EID: 0030610257     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. F. P. Guengerich: Cytochromes P450 of human liver: classification and activity profiles of the major enzymes. In: "Advances in Drug Metabolism in Man." (G. M. Pacifici and G. N. Fraccia. eds.). pp. 181-231. European Commission, Brussels, Belgium, 1995.
2. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drug, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
3. 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 24, 126-136 (1996).
4. J. M. Machinist, M. D. Mayer, M. S. Shet, J. L. Ferrero, and A. D: Rodrigues: Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab. Dispos. 23, 1163-1174 (1995).
5. M. S. Ching, N. Bichara, C. L. Blake, H. Ghabrial, R. H. Tukey, and R. A. Smallwood: Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab. Dispos. 24, 692-694 (1996).
6. K. Brosen: Drug interactions and the cytochrome P450 system: the role of cytochrome P4501A2. Clin. Pharmacokinet. 29, (Suppl. 1) 20-25 (1995).
7. D. Sesardic, M. Pasanen, O. Pelkonen, and A. R. Boobis: Differential expression and regulation of members of the cytochrome P4501A subfamily in human tissues. Carcinogenesis 11, 1183-1188 (1990).
8. J. Buchthal, K. E. Grund, A. Buchmann, D. Schrenk, P. Beaune, and K. W. Bock: Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur. J. Clin. Pharmacol. 47, 431-435 (1995).
9. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. De La Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
10. K. Brosen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1993).
11. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).
12. A. D. Rodrigues and S. L. Wong: The utility of in vitro metabolism-based drug-drug interaction studies in drug discovery and development: attempting in vitro-in vivo correlations. In: "Pharmacogenetics: Bridging the Gap Between Basic Science and Clinical Application." (J. Schlegel, ed.), pp. 6.2.1-6.2.42. Biomedical Library Series, International Business Communications, Southborough, MA, 1996.
13. B. B. Rasmussen, K. K. Nielsen, and K. Brosen: Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 222, 9-13 (1994).
14. M. Bourrie, V. Meunier, Y. Berger, and G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol Exp. Ther. 277, 321-332 (1996).
15. PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. 86, 7696-7700 (1989).
16. A. D. Rodrigues, M. J. Kukulka, B. W. Surber, S. B. Thomas, J. T. Uchie, G. A. Rotert, G. Michel, B. Thome-Kromer, and J. M. Machinist: Measurement of liver microsomal cytochrome P450 (CYP2D6) activity using [O-methyl 14C]dextromethorphan. Anal. Biochem. 219, 309-320 (1994).
17. A. D. Rodrigues: Comparison of aldehyde oxidase activity and cytochrome P450 activities in human liver in vitro. Biochem. Pharmacol. 48, 197-200 (1994).
18. W. Tassaneeyakul, D. J. Birkett, M. E. Veronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. O. Miners: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407 (1993).
19. K. G. Jensen, H. E. Poulsen, J. Doehmer, and S. Loft: Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol. Toxicol. 76, 286-288 (1995).
20. L. M. Distlerath, P. E. B. Reilly, M. V. Martin, G. G. Davis, G. R Wilkinson, and F. P. Guengerich: Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057-9067 (1985).
21. J. Schimder, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. X. Duan, D. Karsov, and R. J. Shader. Characterization of six in vitro reactions mediated by human cytochrome P450: application to testing of cytochrome P450-directed antibodies. Pharmacology 52, 125-134 (1996).
22. A. R. Boobis, G. C. Kahn, C. Whyle, M. J. Brodie, and D. S. Davies: Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem. Pharmacol. 30, 2451-2456 (1981).
23. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
24. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
25. D. J. Waxman, D. P. Lapenson, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and K. Korzekwa: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290, 160-166 (1991).